REINSTATE YOUR SUBSCRIPTION AND SAVE $400

For over 25 years, Generic Line has been the leading resource of accurate, up-to-date news and analysis on FDA policies affecting generic drugs and drug patents.

Each monthly issue keeps you and your firm up to date on crucial regulatory, legislative and business changes, including the latest on:

  • The establishment of a biosimilars approval pathway
  • What Strategies are most successful in challenging blockbuster brands
  • The FTC's growing efforts to stop pay-for-delay agreements.

Plus in every issue you get links to key documents, such as FDA guidances, warning letters, rules, full texts of proposed legislation and more. 


Monthly, 12 issues/year, Electronic delivery.

 
 

$1,097 $697

 

Bonus

Renew Generic Line today and receive a FREE copy of our management report, Expediting the FDA Generic Drug Approval Process – a $397 Value! Plus receive a FREE copy of our webinar, First Cycle Approval of ANDAs — a $287 Value!

Key Benefits

LINKS TO KEY DOCUMENTS — Each issue provides you with links that support GEN's articles such as FDA guidances, warning letters, rules, full texts of proposed legislation and more.

FDANEWS DRUG DAILY BULLETIN — This daily email brings you important FDA and international regulatory, legislative and business news in the pharmaceutical industry.

ONLINE ACCESS — Consider our newsletter archive your personal library! Search your current issue — and hundreds of past issues — by keyword and relevancy.